{"id":822533,"date":"2025-03-06T08:14:26","date_gmt":"2025-03-06T13:14:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/"},"modified":"2025-03-06T08:14:26","modified_gmt":"2025-03-06T13:14:26","slug":"organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/","title":{"rendered":"Organovo Announces the Issuance of Additional Shares  in Conjunction with Warrant Exercises"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, March  06, 2025  (GLOBE NEWSWIRE) &#8212; Organovo Holdings, Inc. (Nasdaq:ONVO) (\u201cOrganovo\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced it has issued additional shares in conjunction with warrant exercises by investors and at-the-market stock sales. An additional 2,967,144 shares of common stock of the Company have been issued. The shares of common stock issuable upon exercise of the outstanding warrants were registered pursuant to a registration statements that was declared effective on May 8, 2024. The aggregate gross proceeds from the exercise of the existing warrants and at-the-market stock sales are expected to total approximately $2.3 million, before deducting financial advisory fees and commissions. After giving effect to the issuance of these additional shares, the Company has 20,421,617 shares of outstanding common stock.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Organovo<\/strong><br \/>\n        <br \/>Organovo\u00a0is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease.\u00a0 For more information visit\u00a0Organovo&#8217;s\u00a0website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_g2VM252ybJ1IDzovKDrE1Tvk-MgqNRlZ2Vn2gGwlTohTqb-WN2RnGwNHsMb_AoAYUgFnZIElDkAnXnxAzBMpTsm3bKOcwP9auUX4vhspvgCX_Sqg_LwioS4rzFWHKdtv5Nc5fGIUXl8AoxWdxk9DKqR3c4AuzqQ2GOXrSbg5BfsU-mkckx3S_nYqGPpN8gbOyse3DS7XkuxAZCvogIPjQq3CnnpGWr-NGZYRayo-4x5fb3fERhYfM-JfT6-PqZVNTNvR9keQxNUh3RscNvXNPXy5wOO1OgRb9wz4nYAxmO3L3UcwHJe3I3UzkK0MGgWDubGnN1O7izv_N5uoMAMk-ubQzONXstMTLgqpoDlMxCTW0KboWo0sJTbnT3DRMqwy3hcYRN_5EU1lRR4xNvOJn8rENVyPxYmVwGHYsXuKpI=\" rel=\"nofollow\" target=\"_blank\">www.organovo.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>\n        <em>Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. These risks and uncertainties and other factors are identified and described in more detail in the Company\u2019s filings with the\u00a0SEC, including its Annual Report on Form 10-K filed with the\u00a0SEC\u00a0on\u00a0May 31, 2024, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the\u00a0SEC\u00a0on\u00a0February 19, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of\u00a0the\u00a0United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.\u00a0<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>Contact<\/strong><br \/>\n        <br \/>CORE IR<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GVle8fIjCpfX8R3xn5WoUpkbvVhereg4lVr72hw5W3PCco01fkEHa5qlywk3CwBdIGxac8epIBwDNHLbq2447w==\" rel=\"nofollow\" target=\"_blank\">pr@coreir.com<\/a><\/p>\n<p align=\"justify\">Source: Organovo, Inc.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTk3NiM2NzkzMzg2IzIwMjAwODU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2E2NjcxNmEtZjk2Yy00YzFmLTgxMmEtNDU2YzY3MDNlZTlhLTEwMzE2NTc=\/tiny\/Organovo-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) &#8212; Organovo Holdings, Inc. (Nasdaq:ONVO) (\u201cOrganovo\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced it has issued additional shares in conjunction with warrant exercises by investors and at-the-market stock sales. An additional 2,967,144 shares of common stock of the Company have been issued. The shares of common stock issuable upon exercise of the outstanding warrants were registered pursuant to a registration statements that was declared effective on May 8, 2024. The aggregate gross proceeds from the exercise of the existing warrants and at-the-market stock sales are expected to total approximately $2.3 million, before deducting financial advisory fees and commissions. After &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Organovo Announces the Issuance of Additional Shares  in Conjunction with Warrant Exercises&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-822533","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) &#8212; Organovo Holdings, Inc. (Nasdaq:ONVO) (\u201cOrganovo\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced it has issued additional shares in conjunction with warrant exercises by investors and at-the-market stock sales. An additional 2,967,144 shares of common stock of the Company have been issued. The shares of common stock issuable upon exercise of the outstanding warrants were registered pursuant to a registration statements that was declared effective on May 8, 2024. The aggregate gross proceeds from the exercise of the existing warrants and at-the-market stock sales are expected to total approximately $2.3 million, before deducting financial advisory fees and commissions. After &hellip; Continue reading &quot;Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-06T13:14:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTk3NiM2NzkzMzg2IzIwMjAwODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises\",\"datePublished\":\"2025-03-06T13:14:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\\\/\"},\"wordCount\":413,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4OTk3NiM2NzkzMzg2IzIwMjAwODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\\\/\",\"name\":\"Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4OTk3NiM2NzkzMzg2IzIwMjAwODU=\",\"datePublished\":\"2025-03-06T13:14:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4OTk3NiM2NzkzMzg2IzIwMjAwODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4OTk3NiM2NzkzMzg2IzIwMjAwODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/","og_locale":"en_US","og_type":"article","og_title":"Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises - Market Newsdesk","og_description":"SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) &#8212; Organovo Holdings, Inc. (Nasdaq:ONVO) (\u201cOrganovo\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced it has issued additional shares in conjunction with warrant exercises by investors and at-the-market stock sales. An additional 2,967,144 shares of common stock of the Company have been issued. The shares of common stock issuable upon exercise of the outstanding warrants were registered pursuant to a registration statements that was declared effective on May 8, 2024. The aggregate gross proceeds from the exercise of the existing warrants and at-the-market stock sales are expected to total approximately $2.3 million, before deducting financial advisory fees and commissions. After &hellip; Continue reading \"Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-06T13:14:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTk3NiM2NzkzMzg2IzIwMjAwODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises","datePublished":"2025-03-06T13:14:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/"},"wordCount":413,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTk3NiM2NzkzMzg2IzIwMjAwODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/","name":"Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTk3NiM2NzkzMzg2IzIwMjAwODU=","datePublished":"2025-03-06T13:14:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTk3NiM2NzkzMzg2IzIwMjAwODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTk3NiM2NzkzMzg2IzIwMjAwODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-warrant-exercises\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/822533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=822533"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/822533\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=822533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=822533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=822533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}